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Chemokines and chemokine receptors are widely expressed by cells of the immune and nervous systems. This review focuses on our
current knowledge concerning the role of chemokines in the pathophysiology of chronic pain syndromes. Injury- or disease-induced
changes in the expression of diverse chemokines and their receptors have been demonstrated in the neural and nonneural elements
of pain pathways. Under these circumstances, chemokines have been shown to modulate the electrical activity of neurons by multi-
ple regulatory pathways including increases in neurotransmitter release through Ca-dependent mechanisms and transactivation of
transient receptor channels. Either of these mechanisms alone, or in combination, may contribute to sustained excitability of primary
afferent and secondary neurons within spinal pain pathways. Another manner in which chemokines may influence sustained neuro-
nal excitability may be their ability to function as excitatory neurotransmitters within the peripheral and central nervous system. As
is the case for traditional neurotransmitters, injury-induced up-regulated chemokines are found within synaptic vesicles. Chemokines
released after depolarization of the cell membrane can then act on other chemokine receptor-bearing neurons, glia, or immune cells.
Because up-regulation of chemokines and their receptors may be one of the mechanisms that directly or indirectly contribute to the
development and maintenance of chronic pain, these molecules may then represent novel targets for therapeutic intervention in
chronic pain states.
I
n his landmark treatise Sir Charles
Scott Sherrington proposed the con-
cept that pain is the evolved re-
sponse to a potentially harmful,
noxious stimulus (1). An example would
be placing your hand on a hot iron and
the resulting sensation of pain, which pro-
duces almost immediate withdrawal,
thereby preventing tissue damage. This
conscious perception of pain is the result
of activity in a set of well defined neural
pathways that start with the primary affer-
ent neurons. These pseudounipolar neu-
rons are responsible for the transmission
of pain (‘‘nociceptors’’) and have unmyeli-
nated or lightly myelinated axons. The cell
bodies of nociceptors are found in the
dorsal root ganglia (DRG). Nociceptors
have both a peripheral connection that
innervates potentially diseased or trauma-
tized nerves, muscles, tendons, organs,
and epithelia, and a centrally projecting
axon that enters the central nervous sys-
tem. This central axon conveys ‘‘nocicep-
tive’’ information to second-order neurons
in the dorsal horn of the spinal cord. Neu-
ral connections from the dorsal horn to
the thalamus, and from there to the cor-
tex, relay this noxious information to
higher centers of conscious experience
(Fig. 1). The central axons of primary af-
ferent nociceptive neurons also provide
information to polysynaptic spinal cord
interneurons, which are essential for the
initiation of the nociceptive withdrawal
reflex. These neurons trigger motor re-
flexes that are important in the avoidance
of potentially harmful painful stimuli (e.g.,
that hot iron). Descending pathways origi-
nating in the cortex and/or midbrain pro-
vide modulatory feedback signals at the
level of the spinal cord that also regulate
the nociceptive experience, thereby pro-
viding a closed-loop feedback control of
this behavior. Additionally, impulses can
travel back along the peripheral axon of
the nociceptive sensory neuron toward the
distal nerve endings, resulting in the local
release of neuropeptides in the injury en-
vironment. This neuropeptide release pro-
duces vasodilatation, venule permeability,
plasma extravasation, edema, and leuko-
cyte influx, a process termed ‘‘neurogenic
inflammation.’’
Although pain clearly plays an impor-
tant survival role in safeguarding the indi-
vidual from potential sources of tissue
destruction, the perception of pain can
also be the result of a dysfunctioning ner-
vous system. Typically, the local response
to various types of injury or infection in-
volves the release of peripheral chemical
mediators. These injury-associated factors
produce two effects. One role is to attract
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Fig. 1. The neural pathway of nociception from primary afferent neurons (PANs) to the superficial
lamina in the dorsal horn of the spinal cord. Second-order neurons in the dorsal horn convey the noxious
signal to the brainstem, midbrain, and thalamus. Finally, third-order neurons relay the electrical signal to
the somatosensory/cingulate cortex and limbic system. Descending modulatory influences arrive in the
spinal cord dorsal horn (dashed lines) and are derived from the midbrain periaqueductal gray (PAG), the
locus ceruleus, and the rostral ventromedial medulla (RVM).
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leukocytes to the point of injury as part of
the inflammatory response (2) and the
other is to sensitize nociceptors, enhanc-
ing their responses to pain (3). This
increased excitatory activity produces
transmitter release in the spinal cord en-
hancing neuronal activity in pain pathways
in the central nervous system, a phenome-
non known as spinal sensitization (4). Un-
der some circumstances, nociceptor-driven
electrical activity in the spinal cord be-
comes divorced from normal physiology,
so that pain is produced in the absence of
any appropriate stimulus (5, 6). This is
now known as pathological or ‘‘neuro-
pathic’’ pain.
Neuropathic pain is experienced in as-
sociation with many types of injury to the
nervous system or as a consequence of
diabetes, cancer, infectious agents (e.g.,
HIV-1), or the toxic side effects of diverse
drug regimens. From the behavioral point
of view, neuropathic pain is associated
with different types of hypersensitive pain
behavior, including allodynia (pain evoked
by a normally innocuous stimulus) and
hyperalgesia (enhanced pain evoked by a
noxious stimulus). In states of neuropathic
pain, abnormal activity occurs in nocicep-
tive neurons throughout the neuraxis. This
activity is thought to result from the in-
creased neuronal expression and activa-
tion of ion channels and receptors that
initiate and mediate the abnormal genera-
tion of action potentials and synaptic
transmission in pain pathways. But what
causes these changes to occur? Presum-
ably something provokes nociceptive neu-
rons to express different sets of genes,
resulting in a new and abnormal chroni-
cally hyperexcitable ‘‘pain’’ phenotype.
From the therapeutic point of view,
neuropathic pain is an extremely intracta-
ble problem. Once established, pain of
this type is not readily susceptible to treat-
ment with nonsteroidal anti-inflammatory
drugs (NSAIDs). Moreover, although opi-
ates may be used for acute or for chronic
pain states (e.g., terminal cancer), allevia-
tion of neuropathic pain is more prob-
lematic because high doses are often
required, narrowing the therapeutic index
(7). The remaining available drugs used to
treat these syndromes (tricyclic antidepres-
sants, antiepileptics) are not particularly
effective and are also associated with
a number of negative side effects (8).
Hence, a complete understanding of the
cellular and molecular processes involved
in the development of neuropathic pain is
essential for the development of novel
therapies.
It has been shown that peripheral nerve
injury (trauma-, disease-, or drug-induced)
can trigger a wide variety of cellular
changes in sensory neurons and, as we
have discussed, neuropathic pain following
peripheral nerve injury is a consequence
of enhanced excitability associated with
the chronic sensitization of nociceptive
neurons in the peripheral and central ner-
vous systems. Interestingly, after a periph-
eral nerve injury, not only a subset of
injured (9–12), but also neighboring non-
injured peripheral sensory neurons exhibit
spontaneous, ectopic discharges (13–18).
Abnormal excitability of pain neurons
may even extend to the spinal cord dorsal
horn contralateral to the nerve injury
(19–23, 69). Although it is clear that mo-
lecular changes in the sensory ganglia and
spinal cord dorsal horn are responsible for
chronic pain, it remains a mystery as to
what event(s) are critical for its develop-
ment and maintenance.
Peripheral Nerve Injury
and Inflammation
One important development in our under-
standing of the cellular and molecular
processes that produce neuropathic pain
concerns the role of the immune system.
Immunity can be dissociated into two
different phases: innate and acquired.
Acquired immunity involves the phenome-
non of immunological memory and in-
cludes the antibody and lymphocyte
responses to specific antigens. The fore-
runner to acquired immunity is the innate
immune response. This more basic type of
immunity involves a generalized immune
cell response to a variety of toxic or
pathological intrusions into physiological
homeostasis. Molecules such as Toll-like
receptors expressed by numerous types of
cells, including leukocytes, Schwann cells,
neurons, astrocytes, and microglia, can
recognize generalized molecular patterns
of infectious agents, cell debris, or other
cellular detritus initiating a cascade of
cytokine synthesis that orchestrates a gen-
eral cellular response to these potential
problems (27–30). As noted above, this
response is inflammatory in nature and
involves the recruitment of leukocytes to
areas of tissue damage. The activation of
innate immune inflammatory responses is
also frequently linked to the development
of pathology. In the present context, it is
believed that the innate immune response
to injury plays a prominent role in the
establishment of chronic pain states, ex-
tending beyond its role in promoting the
Table 1. Chemokine receptor selectivity
Receptor Chemokines, systematic name (functional name)
CC chemokine receptors
CCR1 CCL3 (MIP-1), CCL5 (RANTES), CCL7 (MCP-3), CCL13 (MCP-4)
CCR2 CCL2 (MCP-1), CCL7 (MCP-3), CCL8 (MCP-2), CCL12 (MCP-5), CCL13 (MCP-4)
CCR3 CCL5 (RANTES), CCL7 (MCP-3), CCL8 (MCP-2), CCL11 (Eotaxin), CCL13 (MCP-4), CCL15 (MIP-5), CCL24 (Eotaxin-2), CCL26 (Eotaxin-3)
CCR4 CCL2 (MCP-1), CCL3 (MIP-1), CCL5 (RANTES), CCL17 (TARC), CCL22 (MDC)
CCR5 CCL3 (MIP-1), CCL5 (RANTES), CCL8 (MCP-2), CCL14 (MIP-1)
CCR6 CCL20 (Exodus-1/LARC/MIP-3)
CCR7 CCL19 (Exodus-3/ELC/MIP-3), CCL21 (Exodus-2/SLC/6Ckine)
CCR8 CCL1 (I-309), CCL17 (TARC), CCL19 (Exodus-3/ELC/MIP-3)
CCR9 CCL2 (MCP-1), CCL3 (MIP-1), CCL5 (RANTES), CCL8 (MCP-2), CCL11 (Eotaxin), CCL13 (MCP-4), CCL14 (MIP-1), CCL25 (TECK)
CCR10 CCL27 (CTACK), CCL28 (MEC)
CCR11 CCL2 (MCP-1), CCL19 (Exodus-3/ELC/MIP-3), CCL21 (Exodus-2/SLC/6Ckine), CCL25 (TECK)
CXC chemokine receptors
CXCR1 CXCL6 (GCP-2), CXCL8 (IL-8)
CXCR2 CXCL1 (GRO-) CXCL2 (GRO-), CXCL3 (GRO-), CXCL5 (ENA-78), CXCL6 (GCP-2), CXCL7 (NAP-2), CXCL8 (IL-8)
CXCR3 CXCL10 (IP-10), CXCL9 (MIG), CXCL11 (ITAC)
CXCR4 CXCL12 (SDF-1)
CXCR5 CXCL13 (BLC)
CXCR6 CXCL16
CXCR7 CXCL11 (ITAC), CXCL12 (SDF-1)
CX3C chemokine receptor
CX3CR1 CX3CL1 (Fractalkine)
C chemokine receptor
XCR1 XCL1 (Lymphotactin), XCL2 (SCM-1b)
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influx and activation of leukocytes. Al-
though inflammatory and neuropathic
pain syndromes are often considered dis-
tinct entities, emerging evidence suggests
that proinflammatory substances pro-
duced in association with the innate im-
mune response are clearly implicated in
the actual development and maintenance
of neuropathic pain and may be a neces-
sary prelude to its development. As such,
both neuroinflammatory and associated
immune responses following nerve dam-
age may contribute as much to the devel-
opment and maintenance of neuropathic
pain as the initial nerve damage itself.
The traditional view has been that the
influx of leukocytes associated with in-
flammation was responsible for secreting
the chemical mediators that produced
pain. However, as we will discuss, current
evidence suggests that the role of the in-
flammatory response in the generation of
pain is not limited to effects produced by
the influx of leukocytes per se. Thus, it is
currently believed that the proinflamma-
tory cytokines that drive chronic pain be-
havior may be derived from the cellular
elements of the nervous system itself, and
that these molecules can act directly on
receptors expressed by neurons and other
cells of the nervous system. The effects
produced by these factors may lead to
chronic hyperexcitability and alterations in
gene expression by nociceptors, abnormal
processing of pain signals, and enhanced
pain states. In this way, signaling pathways
designed to facilitate a protective response
to tissue injury become sources of chronic
pathological pain.
The question then arises as to exactly
which inflammatory cytokines are con-
cerned in the establishment of chronic
pain and the molecular processes that un-
derlie pain hypersensitivity. The innate
immune response is associated with the
development of a complex cascade of cy-
tokine expression in which many inflam-
matory mediators are synthesized in a
mutually dependent manner. It is likely
that several of these inflammatory media-
tors are concerned in the establishment of
the ‘‘pain’’ phenotype that characterizes
neuropathic pain.
One family of cytokines that has re-
cently come to light as playing a central
role in the induction and maintenance of
chronic pain are the CHEMOtactic cyto-
KINES (chemokines). Chemokines are
small, secreted proteins that exert all of
their known effects through the activation
of a family of related G protein-coupled
receptors (GPCRs). Chemokines were
originally identified because of their che-
moattractant effects that control the mi-
gration of different classes of leukocytes
in association with the development of
inflammation (2). Several subfamilies of
chemokines and their receptors are known
to exist (Table 1). Most chemokines are
not constitutively expressed at high levels,
their production and secretion being nor-
mally associated with activation of the
inflammatory response (Fig. 2). An excep-
tion to this rule is the chemokine, stromal
cell-derived factor-1 (SDF-1/CXCL12).
SDF-1 is the most evolutionarily ancient
member of the chemokine family; it ex-
isted phylogenetically before the develop-
ment of an immune system, indicating
that chemokine signaling originally played
a role other than the regulation of leuko-
cyte chemotaxis (31, 32). Still, chemotaxis
appears to be one ancient function of this
chemokine as well. In mammals, SDF1
signaling through its major receptor,
CXCR4, has been shown to be important
for the development of the embryo, where
SDF-1 regulates the migration of the
stem/progenitor cells that form numerous
tissues (33, 34). Postnatally, this signaling
system is still used in this way to retain
hematopoietic stem cells in the bone mar-
row (35).
Although chemokines clearly have a
central role in orchestrating the normal
inflammatory response, the pathogenesis
of many chronic inflammatory conditions
such as atherosclerosis, arthritis, and in-
flammatory bowel disease has been shown
to be mediated in large part by the actions
of chemokines (2). In addition, numerous
neurological conditions accompanied by
activation of the innate immune response
during their onset or progression appear
to involve the action of chemokines in
their pathogenesis. These include autoim-
mune disorders (e.g., multiple sclerosis),
neurodegenerative disorders (e.g., cerebral
ischemic injury, Parkinson’s, Huntington’s,
and Alzheimer’s diseases), as well as virus-
based diseases (e.g., HIV-1 and herpes
simplex) (36–38). This chemokine-
mediated component is also likely to ex-
tend to the pathogenesis and maintenance
of chronic pain in both disease-related
conditions (e.g., multiple sclerosis, HIV-1,
and herpes simplex) and after trauma, all
of which are associated with innate im-
mune responses and prolonged expression
of chemokines and their receptors by the
cellular elements of the nervous system
(39). This being the case, interference
with chemokine function represents a
promising approach for the development
of both novel anti-inflammatory medica-
tion and the treatment of chronic pain
conditions.
Chemokines and Their Receptors in
Acute and Chronic Pain
There is now a large amount of data indi-
cating that, as with other cytokines, che-
mokines and their receptors can influence
both the acute and chronic phases of pain.
However, why is chemokine function of
particular interest in this regard? As indi-
cated above, it has become apparent that
the cellular elements of the nervous sys-
tem (e.g., neurons, glia, and microglia) are
able to both synthesize and respond to
chemokines, something that is quite inde-
pendent of their role in the regulation of
leukocyte chemotaxis and function. Oh et
al. (40) first demonstrated that the simple
injection of the chemokines SDF-1, Regu-
Skin
G.I.
Fractalkine
MCP-1/CCR2 
RANTES/CCR5
IP-10/CXCR3
SDF1/CXCR4
n/c Fractalkine
Muscle
Glogi tendon organs/muscle spindles
Peripheral TargetsNormal
Post-injury
CCR2, CX3CR1
n/c CCR2, CX3CR1
Primary
Afferent
Neuron
Spinal Cord
Fig. 2. Peripheral and central targets of primary afferent neurons. (Upper) The somas of nociceptive
neurons are housed togetherwithmyelinating Schwann cells and nonmyelinating Schwann cells (satellite
cells) in the dorsal root ganglia (DRG). These pseudounipolar neurons communicate with both peripheral
target tissue (epithelia, muscle, and visceral organs) and neuronal/nonneuronal elements of the spinal
cord dorsal horn (neurons, microglia, and astrocytes). Some chemokine/receptors are present in both CNS
and PNS cellular elements. (Lower) Following injury, compromised sensory neurons and adjacent non-
neuronal cells produce chemokines and their receptors within the DRG (n/c indicates no change in mRNA
or protein expression). These chemokines can be released within the DRG as well as from axons in
peripheral target tissue and spinal cord dorsal horn. Increased cellular signaling between chemokines and
receptors may be responsible for changes in neuronal excitability.
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lated upon Activation, Normal T cell Ex-
pressed, and Secreted (RANTES/CCL5)
or macrophage inflammatory protein-1
(MIP-1/CCL3) into the adult rat hind
paw produced dose-dependent tactile allo-
dynia. Indeed, these authors demonstrated
that cultured DRG neurons expressed
numerous types of chemokine receptors,
indicating that the observed pain behavior
might result from a direct action of che-
mokines on these neurons. In support of
this possibility, chemokines were found to
strongly excite DRG neurons in culture
(41, 42) and chemokine-induced excitation
was associated with the release of pain
related neurotransmitters such as Sub-
stance P and calcitonin gene-related
peptide (CGRP) (43, 44). The cellular
mechanism underlying chemokine-induced
excitation of sensory neurons in culture
has been shown to have at least two com-
ponents. The first of these components is
the transactivation of transient receptor
potential cation channels (TRP), such as
TRPV1 and TRPA1, which are also ex-
pressed by populations of nociceptive
neurons (44–46) (Fig. 3). The second
component is the inhibition of K con-
ductances that normally regulate neuronal
excitability. MIP-1, for example, can en-
hance the thermal sensitivity of TRPV1
(47). The receptor for MIP-1, CCR1, is
expressed by 85% of cultured DRG
neurons, which also express TRPV1 (47).
Activation of other chemokine receptors,
such as CCR2 expressed by cultured
DRG neurons (see below), also produces
excitation through transactivation of both
TRPV1 and TRPA1 (44) (Fig. 3). In the
former instance the mechanism of activa-
tion appears to be due to phospholipase
C-induced removal of tonic PIP2-
mediated channel block (48), whereas in
the second instance the transactivation
appears to involve a PKC-mediated event
(49–51). Importantly, TRPA1 activation is
central to acute pain, neuropeptide re-
lease, and neurogenic inflammation (52,
53). These data suggest that chemokine-
induced excitation involving TRP channel
activation may be of key importance in
driving the increased excitation observed
in chronic pain states.
A significant question is whether such
data, mostly obtained in cell culture stud-
ies, has relevance to the situation prevail-
ing in chronic pain states in vivo. More
recent evidence supporting a key role for
chemokines and their receptors in chronic
pain has come from the results of experi-
ments using several accepted models of
neuropathic pain in rodents. These models
include sciatic nerve transaction (54, 55),
partial ligation of the sciatic nerve (26, 56,
57), chronic constriction injury of the sci-
atic nerve (58–60), chronic compression
of the L4L5 DRG (CCD), a rodent model
of spinal stenosis (41, 42), lysophosphati-
dylcholine-induced focal nerve demyelina-
tion (ref. 44;), bone cancer pain (61, 62),
and zymosan-induced inflammatory pain
(58, 63, 64). Each of these models resulted
in up-regulation of one or more chemo-
kine receptors by DRG neurons associ-
ated with, or in close proximity to, the
injury. Moreover, in several instances it
has also been demonstrated that sensory
neurons will actually up-regulate the syn-
thesis of chemokines in addition to their
cognate receptors (Fig. 4) (41, 42, 44, 65).
Thus, in association with chronic pain the
same DRG neuron may up-regulate both
a chemokine and its receptor, suggesting
some form of cell autologous regulation
of DRG excitability by these molecules
may occur. For example, it might be imag-
ined that under these circumstances DRG
neurons could release chemokines that
would then activate receptors expressed by
the same neuron or others in the vicinity.
Because chemokines can excite DRG neu-
rons, this process might contribute to the
neuronal hyperexcitability observed under
these conditions. As chemokines are also
of central importance in the recruitment
of leukocytes, they would have a unique
role in simultaneously coordinating in-
flammation and neuronal excitability.
One good example of the validity of
this type of model concerns the potential
role of the chemokine MCP-1 and its re-
ceptor CCR2 in the genesis of neuro-
pathic pain. The role of MCP-1/CCR2
signaling was first intimated in neuro-
pathic pain states following peripheral
nerve injury in genetically engineered
mice lacking CCR2 receptors. These re-
ceptor knockout mice failed to display
mechanical hyperalgesia after partial liga-
tion of the sciatic nerve without a detect-
able change in acute pain behavior (56),
whereas transgenic mice overexpressing
glial MCP-1 exhibited enhanced nocicep-
tive responses (66).
In keeping with these results, exogenous
administration of MCP-1 produced both
membrane threshold depolarization and
action potentials in a subpopulation of
small, medium, and large neurons in the
intact DRG from animals with neuro-
pathic pain resulting from chronic com-
pression of the DRG (CCD) (41, 42).
Examination of the expression pattern for
CCR2 receptors in the DRG demon-
strated that they were not normally ex-
pressed by DRG neurons in vivo, but were
extensively up-regulated in models of neu-
ropathic pain where they were usually
present in the same neurons that up-
Fig. 3. Crosstalk among chemokine receptors, bradykinin, and transient receptor potential channels
(TRP). (Upper) In sensory neurons, treatment with the proinflammatory bradykinin peptide results in
hyperalgesia. Bradykinin also enhances the sensitivity of TRPV1 and TRPA1, through a signal transduction
cascade involving Gi protein, PLC, and PKC. PLC hydrolyzes phosphoinositol 4,5-biphosphate (PIP2), an
endogenous inhibitor of TRPV1, thereby sensitizing the TRPV1 pain receptor. Activation of PKC can
simultaneously produce activation of TRPA1 receptors. (Lower) Nerve injury up-regulates the chemokine
receptor, CCR2. Activation of CCR2 by MCP-1 can now sensitize nociceptors via transactivation of the
transient receptor potential channels, TRPV1 and TRPA1. Injury-induced up-regulation of MCP-1/CCR2
signaling by sensory neurons may participate sustained excitability of primary afferent neurons.
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regulated the expression of MCP-1 under
the same circumstances (42) (Fig. 4).
Appropriately, the excitatory electrophysi-
ological effects of MCP-1 were not ob-
served in control animals. Subsequently,
two ionic mechanisms contributing to the
excitatory effects of MCP-1 were identi-
fied in acutely dissociated small-diameter
DRG neurons isolated from animals
previously subjected to CCD. MCP-1
activated a non-voltage-dependent,
depolarizing current with properties of a
nonselective cation conductance, quite
possibly a TRP channel consistent with
the data obtained in cell culture studies
(44), and it also inhibited a voltage-
dependent outward current (41).
Such chemokine-induced excitatory
effects on sensory neurons may further
facilitate the axonal transport and the re-
lease of excitatory neuropeptides, such as
CGRP (43) and Substance P from the
terminals of DRG neurons in the spinal
cord. Zhang and De Koninck recently
demonstrated that MCP-1 is also present
in central afferent fibers in the spinal cord
(59). Thus, electrical activity due to pe-
ripheral nerve injury may also stimulate
central afferent release of MCP-1 into the
spinal cord dorsal horn, further activating
CCR2-expressing glial cells or central neu-
rons (56, 59, 67). Neurons from the dorsal
horn express CCR2 receptors and MCP-1/
CCR2 signaling reduces the inhibitory
effects of GABA on these cells. Hence,
release of MCP-1 may mediate excitatory
effects both at the level of the DRG and
spinal cord.
Overall, these results suggest that
MCP-1 may function as an up-regulatable
neurotransmitter in DRG neurons, whose
expression is associated with the develop-
ment of states of chronic pain hypersensi-
tivity. Examination of the distribution of
MCP-1 at a subcellular level after its
synthesis in cultured DRG neurons has
revealed that it is initially processed by the
trans-Golgi network and packaged into
the same synaptic vesicles as the peptide
neurotransmitter CGRP (44). Vesicles
that contain both proteins can be ob-
served in the neuronal soma and after
transport to nerve terminals. Depolar-
ization of these neurons results in Ca-
dependent release of MCP-1 either from
the soma or nerve terminals (44). Presum-
ably, release of the chemokine from the
cell soma within the DRG would have the
effect of depolarizing neighboring CCR2-
expressing neurons, eliciting excitation and
promoting further MCP-1 release within
the DRG or within the dorsal horn or the
spinal cord where it could interact with
CCR2-expressing neurons and glia. In this
way up-regulation of MCP-1 and CCR2
might be an important trigger for the up-
regulation of DRG hyperexcitability and
maintenance of chronic pain. Note that in
the brain the chemokine CCL21/exodus
has also been shown to be up-regulated by
neurons after excitotoxic stimulation and
to be packaged into secretory vesicles and
released on neuronal depolarization (68).
Thus, it appears that when chemokines
are expressed in neurons under different
circumstances they may generally play a
novel role as neurotransmitters. MCP-1
and CCR2, as well as certain other che-
mokines and chemokine receptors, exhibit
an exceptionally prolonged up-regulation
in the injury-associated DRG (42, 59) and
the trigeminal ganglion following periph-
eral nerve injury§ or herpes simplex virus
infection (70–72), supporting the possi-
bility that this type of signaling could
contribute to the chronic nature of
neuropathic pain.
Overall, the evidence suggests that pro-
longed chemokine and chemokine recep-
tor expression in sensory ganglia may well
be a significant contributor to many
injury-induced and virus-associated neuro-
pathic pain syndromes. This being the
case, it is also of interest to define the
signaling pathways in DRG neurons that
result in the up-regulation of chemokine
and chemokine receptor expression be-
cause they may represent novel targets for
intervention in the treatment of chronic
pain. In the case of CCR2 receptors some
information on this issue has been ob-
tained. Analysis of the structure of the
mouse and human CCR2 genes revealed
several upstream regulatory elements that
might potentially mediate the action of
different transcription factors. Included in
these is a conserved binding site for the
transcription factor, nuclear factor of acti-
vated T cells (NFAT) (73). Members of
the NFAT family of proteins are ex-
pressed by DRG neurons, and expression
of constitutively active NFAT derivatives
produced up-regulation of CCR2 recep-
tors in these neurons (73). NFAT is acti-
vated by being dephosphorylated by the
Ca-dependent phosphatase calcineurin.
When [Ca]i is increased in DRG neurons
after depolarizing and Ca influx by
voltage-dependent Ca channels, for exam-
ple, calcineurin and NFAT are activated,
resulting in the up-regulation of CCR2
expression (73). This then provides a pos-
sible pathway for the induction of CCR2
in the context of neuropathic pain. An
injury-induced upstream mediator is en-
visaged as initially depolarizing DRG neu-
rons, leading to Ca influx and CCR2
up-regulation. Once up-regulated, signal-
ing by CCR2 could increase DRG excita-
§White F, Bauer W, Jellish W, Chan D, LaMotte R, Miller R,
25th Annual Scientific Meeting of the American Pain So-
ciety, May 3–6, 2006, San Antonio, TX, poster 682.
Fig. 4. Primary afferent neurons express MCP-1 and CCR2 in association with peripheral neuropathy.
Sciatic nerve demyelination injury was induced by lysophosphatidylcholine (LPC) in CCR2-EGFP BAC
transgenic mice. DRG were isolated at postoperation day (POD) 14, cryosectioned, and subjected to
immunohistochemistry by using a polyclonal anti-MCP-1 antibody. (A–C) Sham-operated control. (D–F)
LPC-treated group. Note thatmany neuronal cell bodies express bothMCP-1 andCCR2. In addition,MCP-1
is also observed innumerous axonprocesses throughout theganglion. (G–I) TRPV1-expressingnociceptors
(red arrows) up-regulated CCR2 expression (yellow arrow). Some of larger neurons that do not express
TRPV1 also expressed CCR2 (green arrow). (Scale bars, 100m.) [Reproducedwith permission from ref. 44.
(Copyright 2007, Blackwell).]
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tion further and potentiate ongoing
excitability. Interestingly, although MCP-1
is up-regulated by DRG neurons together
with CCR2 in chronic pain (42), MCP-1 is
not a target gene for NFAT regulation.
However, we have observed that MCP-1
is up-regulated in DRG neurons by the
action of the cytokine TNF- (73). In-
deed, TNF- is known to increase the
excitability of DRG neurons (74, 75). Po-
tential sources of TNF- release include
the cells associated with the peripheral
injury site and glial cells adjacent to pri-
mary afferent neuron central projections
within the spinal cord (microglia and as-
trocytes) (84, 105). Thus, TNF- may be
the upstream regulator of chemokine sig-
naling in these cells. Such a possibility
would also help to explain why increased
DRG excitability extends to neurons that
are both ipsilateral and contralateral to
the injured neurons, observations that
suggest an important role for a diffusible
mediator in triggering these events.
Although most of the data obtained on
chemokine signaling in the DRG in the
context of neuropathic pain concerns the
role of MCP-1/CCR2, it is clear that other
types of chemokine signaling may also be
dynamically regulated under similar condi-
tions. Up-regulated expression of the
CXCR3, CXCR4, and CCR5 receptors,
and their chemokine ligands, has also
been observed in populations of DRG
neurons in chronic pain models (69). As
with CCR2, up-regulation of some of
these chemokine receptors appears to be
NFAT-dependent (e.g., CCR5), whereas
others do not (e.g., CXCR4) (73). The
precise expression patterns and time
course of up-regulation of these diverse
chemokine signaling systems differs in
each case, and so the details of how they
each participate in pain behavior may vary
according to the circumstances and will
require further clarification. Nevertheless,
in so far as they have been investigated, it
appears that all of these chemokines are
packaged into neurotransmitter secretory
vesicles in DRG neurons (44, 68). It is
interesting that, in the case of SDF-1 and
MCP-1, these vesicle populations are
clearly different (unpublished observa-
tions), indicating that even when two che-
mokines are secreted by the same neuron
they may subserve somewhat different
functions.
As an example of the role of chemo-
kine signaling in chronic pain one might
consider PNS and CNS inflammatory de-
myelinating diseases such as Guillain–
Barre´ syndrome, Charcot–Marie–Tooth
disease types 1 and 4, and multiple sclero-
sis, which are frequently accompanied by
a neuropathic pain syndrome (76, 77).
Epidemiological studies suggest that
chronic pain syndromes afflict 50–80% of
patients with multiple sclerosis and 70–
90% of individuals with Guillain–Barre´
syndrome (78). Disease-related compo-
nents that may be central to this neuro-
pathic pain symptomology include axon
and Wallerian degeneration (79), which
may act as a trigger for the cytokine cas-
cades that result in the up-regulation and
chronic expression of chemokines and
their cognate receptors (2, 80).
Studies of several rodent models of
demyelinating diseases known to elicit
neuropathic pain behavior include late-
developing peripheral axon demyelination
in periaxin knockout mice (81), lysophos-
phatidylcholine-induced transient focal
demyelination of the sciatic nerve in mice
and rats (44, 69, 82), and the late, acute
clinical phase of experimental autoim-
mune neuritis (83), and indicate a possible
role of chemokine-influenced chronic pain
in these models. Recent studies on rats
and mice subjected to transient focal de-
myelination of the sciatic nerve revealed
chronic up-regulation of MCP-1 and IFN-
-inducing protein-10 (IP-10/CXCL10)
and the chemokine receptors, CCR2,
CCR5, and CXCR4 in primary sensory
neurons (69). Application of these same
chemokines to neurons isolated from
DRG of animals after demyelination pro-
duced an increase in excitation. Thus, up-
regulation of these chemokines and their
receptors may effectively drive the chronic
excitability and pain behavior in demyeli-
nating diseases of this type. It is also of
interest that administration of small mole-
cule CCR2 receptor antagonists to these
animals afforded some relief from ongo-
ing pain, further indicating the role of
chemokine signaling and the potential
therapeutic effectiveness of inhibiting
these events (69).
Chemokines, Glia and Chronic Pain
The preceding discussion has focused on
the role of chemokines and their receptors
expressed by neurons, in particular. How-
ever, it is clear that these molecules are
expressed by other types of cells in the
DRG and CNS which may also participate
in the development and maintenance of
neuropathic pain. Some chemokine and
chemokine receptor signaling events after
peripheral injury or infection appear to be
primarily mediated by molecular and/or
morphological remodeling of glial cells
that, in turn, become a source of inflam-
matory mediators. It has been proposed
that such ‘‘activated’’ Schwann cells, astro-
cytes, and microglia also play an essential
role in the development of chronic pain
hypersensitivity (84). Indeed, drugs that
inhibit the activation of these cells also
seem to interfere with the development of
chronic pain behavior, presumably by sup-
pressing the release of inflammatory me-
diators such as chemokines associated
with their activation.
One of the recent breakthroughs in
pain research has been recognition that
reciprocal communication between neu-
rons and microglia is important in regulat-
ing the quiescent and reactive states
of glial cells. In addition to the glial re-
ceptors for ATP, neuropeptides, neuro-
transmitters, and neurotrophic factors,
chemokines and their receptors appear to
also contribute to these events. Activated
astrocytes and microglia are also rich
sources of chemokine production that
could then interact with pain-related
mechanisms in the dorsal horn and higher
up the neuraxis (29). A clear example of
the central role for chemokine signaling
in mediating communication between
DRG neurons and microglia in the spinal
cord involves the chemokine fractalkine/
CX3CL1 and its receptor, CX3CR1. Frac-
talkine has an unusual structure in that it
is tethered to the membrane by means of
a transmembrane mucin-like stalk. Nor-
mally, fractalkine is expressed by neurons
and its receptor is particularly highly ex-
pressed by microglia (64). Fractalkine can
signal to its receptor on target cells in a
‘‘tethered’’ state or it can be released after
proteolytic cleavage producing a soluble
form of the chemokine that can act at a
distance (58). Injection of fractalkine into
the spinal cord produces pain hypersensi-
tivity and it has been observed that solu-
ble fractalkine is produced in some
chronic pain models (57, 58, 85, 86). Re-
cent studies have revealed how fractalkine
may act in vivo. It has been demonstrated
that the enzyme cathepsin S, which can
cleave tethered membrane-bound fracta-
lkine to its soluble form, can itself be re-
leased from activated microglia (87). The
released fractalkine can then act on mi-
croglia to up-regulate the release of
proallodynic inflammatory mediators.
Thus, fractalkine may act as a neuronal to
glial messenger that amplifies ongoing
pain producing mechanisms. This model
also illustrates the fact that neurons and
glia can interact in a variety of complex
ways to elaborate ongoing pain stimuli,
producing the mediators that may then
initiate transcriptional changes resulting in
chronic neuronal hyperexcitability and
pain. In addition to the example of fracta-
lkine, activated spinal microglia also ex-
press CCR2 and CXCR3 receptors,
making them potential targets for MCP-1
or IP-10 up-regulated and released from
DRG neurons (56, 88, 89).
Glia in the DRG and peripheral
nerve may also represent a source of,
and a target for, the action of chemo-
kines. For example, in response to nerve
injury MCP-1 is up-regulated in
Schwann cells (55, 90, 91). Thus, these
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cells might also represent a source of
chemokine release for the activation
of CCR2 chemokine receptors up-
regulated in adjacent DRG neurons.
The key involvement of chemokine sig-
naling between glia and DRG neurons
appears to be likely in certain chronic
pain states such as those experienced in
association with HIV-1 infection. This has
particular relevance for the present discus-
sion because the cellular receptors for
gp120, the HIV-1 coat protein, are the
CXCR4 and CCR5 chemokine receptors.
One example of an HIV-1-associated pain
syndrome is distal symmetrical polyneu-
ropathy (DSP), which affects as many as
one third of all HIV-1-infected individuals
(92). This painful sensory neuropathy fre-
quently begins with paresthesias in the
fingers and toes progressing over weeks to
months, followed by the development of
pain, often of a burning and lancinating
nature, which can make walking very
difficult. Measurements of pain hypersen-
sitivity have demonstrated allodynia and
hyperalgesia in HIV-1-infected individu-
als. Interestingly, as is the case of HIV-1-
associated effects on the CNS, there is no
productive infection of peripheral neurons
by the virus. Thus, indirect effects of
HIV-1 must lead to the development of
this pain state.
In addition to the effects of inflamma-
tory mediators (including chemokines)
released by virally infected leukocytes,
there are at least two ways in which HIV-
1-induced DSP may involve the direct
effects of HIV-1 gp120 on chemokine
receptors in the DRG: (i) viral protein
shedding in the peripheral nervous system
might enable gp120 to produce painful
neuropathy via glial to neuronal signaling
in the DRG and/or spinal cord (93, 94)
or (2) by the direct activation of CCR5/
CXCR4-bearing sensory neurons by gp120
(40, 95, 96). Indeed, Keswani and col-
leagues have presented a model in which
gp120 can act in both these ways (93, 97).
In the first instance these authors have
demonstrated that binding of gp120 to
CXCR4 receptors expressed by DRG sat-
ellite glial cells up-regulates the release of
the chemokine RANTES which can then
activate CCR5 receptors expressed by
DRG neurons. In the second instance,
gp120 can directly bind to and activate
CXCR4 receptors expressed by DRG
neurons (40). Moreover, this initial excita-
tion of DRG neurons by gp120 and/or
glial mediators might produce Ca2-
dependent up-regulation of CCR2 expres-
sion by these neurons by the mechanisms
discussed above (73), leading to a second
level of chemokine-mediated excitation. In
support of such a model we have ob-
served that treatment of the sciatic nerve
with a T-tropic gp120 subsequently leads
to MCP-1 and CCR2 up-regulation (un-
published observations), which would also
be expected to promote excitation of
DRG neurons.
Complicating matters further, AIDS
patients who are treated by highly active,
antiretroviral therapeutical (HAART)
agents can also develop a painful sensory
neuropathy. Intriguingly, the symptoms of
this syndrome are clinically indistinguish-
able from those of HIV-1-induced DSP,
including a burning sensation in the hands
and feet and hypersensitivity to pain (92,
98, 99). The fact that the two syndromes
are usually seen in association with one
another makes diagnosis more difficult.
Recent studies have shed new light on
the mechanisms of HAART-induced DSP
and the role of chemokine signaling, in
particular. It was observed that the drug,
2,3-dideoxycytidine (zalcitabine or ddC),
produced neuropathic pain behavior to-
gether with up-regulated expression of
both SDF-1 and CXCR4 in DRG satellite
glial cells and some neurons. This suggests
that SDF-1 release from DRG glia might
be involved in the autologous regulation
of excitatory substances from these same
cells and that released SDF-1 might also
directly excite DRG neurons. Significantly,
zalcitabine-induced pain was completely
blocked by the CXCR4 antagonist
AMD3100, illustrating the key role of
CXCR4 signaling in this behavior (65).
Hence, the proallodynic actions of both
HIV-1 and of zalcitabine depend on che-
mokine signaling between DRG glia and
neurons.
Chemokine Interactions with
Other Neurotransmitters
As we have discussed, chemokines and
their receptors expressed by DRG neu-
rons in chronic pain conditions may con-
tribute to nociceptor hyperexcitability in
many instances by directly exciting these
neurons. However, other consequences of
chemokine signaling may also indirectly
contribute to pain behavior. One impor-
tant example of this concerns chemokine
interactions with the endogenous opioid
system. Generally speaking, activation of
-opioid receptors in the DRG and dorsal
horn reduces neuronal excitability and
synaptic transmission at synapses between
nociceptors and first-order neurons in the
spinal cord. This is believed to be one of
the mechanisms by which opiates reduce
pain behavior. However, it has been dem-
onstrated that up-regulation of chemokine
signaling consistently down-regulates
-opioid receptor function (47, 100). One
mechanism through which this may occur
is by heterologous desensitization resulting
from the effects of chemokine receptor
activation on -receptor function (101,
102). In addition, FRET studies have
demonstrated that some chemokine re-
ceptors can directly dimerize with -
opioid receptors, raising the possibility
that this interaction may also alter -
receptor signaling (103). Interestingly, the
opposite may also be true as the -opiate
receptor agonist [D-Ala2,N-MePhe4,Gly5-
ol]enkephalin can down-regulate chemo-
kine activation of chemokine receptors,
something that may account for opiate
drug-induced immune suppression (104).
As we have discussed, chemokines ex-
pressed by DRG neurons may also be
responsible for chemoattractant effects
resulting in leukocyte influx into the gan-
glia. Some leukocytes can actively secrete
opioid peptides, an action that is poten-
tially analgesic (24, 25). Thus, chemo-
kines may be potentially proalgesic by
directly exciting DRG neurons and
down-regulating opioid signaling as well as
potentially analgesic owing to their effects
on endorphin release from leukocytes.
How these diverse effects play out in the
context of chronic pain behavior is incom-
pletely understood and may have different
degrees of importance depending on the
precise type of pain syndrome under con-
sideration. Clearly, however, there are
numerous cellular mechanisms through
which up-regulated chemokine signaling
might result in pain hypersensitivity or
related phenomena.
Conclusions
Recent research has made it clear that
inflammatory processes are critical for the
development of states of chronic pain and
for the changes in behavior of pain neu-
rons that accompany these syndromes.
The development of such behavior may
involve reciprocal signaling interactions
between the different cellular elements of
the central and peripheral nervous sys-
tems. As we have discussed here, chemo-
kines seem to be one set of molecules that
play a key role in coordinating injury as-
sociated nociceptive events as they serve
to regulate inflammatory responses and
can simultaneously act on elements of the
nervous system. Importantly, chemokines
in DRG neurons seem to act as up-
regulatable neurotransmitters that pro-
duce excitatory effects in the DRG and
spinal cord through a variety of mecha-
nisms. The ability of small molecule an-
tagonists of CCR2 and CXCR4 receptors
to ameliorate ongoing pain hypersensitiv-
ity in animal models clearly indicates the
importance of chemokine signaling in this
behavior. We therefore conclude that tar-
geting the chemokine system may provide
a novel form of therapeutic intervention
into states of chronic pain.
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